IL4R and Alzheimer disease: This inhibition extends to the release of proinflammatory cytokines and immunoglobulin E. As of now, dupilumab stands as the sole biologic therapy directed at IL-4Rα that has obtained approval from the United States Food and Drug Administration (FDA) for use in AD.